PT - JOURNAL ARTICLE AU - Meng, Zhongji AU - Wang, Tongyu AU - Chen, Li AU - Chen, Xinhe AU - Li, Longti AU - Qin, Xueqin AU - Li, Hai AU - Luo, Jie TI - An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area AID - 10.1101/2020.04.11.20061473 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.11.20061473 4099 - http://medrxiv.org/content/early/2020/04/17/2020.04.11.20061473.short 4100 - http://medrxiv.org/content/early/2020/04/17/2020.04.11.20061473.full AB - Objective To investigate the efficacy and safety of recombinant human interferon alpha1b (rhIFN-α) nasal drops in healthy medical staff to prevent 2019 novel coronavirus disease (COVID-19).Methods A prospective, open-label study was conducted. Starting January 21, 2020, at Taihe Hospital in Shiyan City, Hubei Province, 2944 medical staff members were recruited and allocated into a low-risk group or a high-risk group according to whether they were directly exposed to the coronavirus. Participants in the low-risk group received rhIFN-α nasal drops (2-3 drops/nostril/time, 4 times/day) for 28 days; those in the high-risk group received rhIFN-α nasal drops combined with thymosin-α1 (1.6 mg, hypodermic injection, once a week). The primary outcome was new-onset COVID-19 over 28 days. The secondary outcome was new-onset fever or respiratory symptoms but with negative pulmonary images. The results were compared with the number of new cases in medical staff in the same areas of Hubei Province (including Wuhan) during the same period. Adverse reactions to interferon nasal drops were also observed.Results Among the 2944 subjects in our study, 2415 were included in the low-risk group, including 997 doctors and 1418 nurses with average ages of 37.38 and 33.56 years, respectively; 529 were included in the high-risk group, including 122 doctors and 407 nurses with average ages of 35.24 and 32.16 years, respectively. The 28-day incidence of COVID-19 was zero in both the high- and low-risk groups. The 28-day incidence of new-onset clinical symptoms with negative images for pneumonia was also zero in both the high- and low-risk groups. As controls, a total of 2035 medical personnel with confirmed COVID-19 pneumonia from the same area (Hubei Province) was observed between January 21 to February 23, 2020. There were no serious adverse effects in the 2944 subjects treated during the intervention period.Conclusion In this investigator-initiated open-label study, we observed that rhIFN-α nasal drops can effectively prevent COVID-19 in treated medical personnel. Our results also indicate that rhIFN-α nasal drops have potential promise for protecting susceptible healthy people during the coronavirus pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04320238Funding StatementThis work was supported by the National Science and Technology Major Project (Grant No. 2018ZX10723203 and 2018ZX10302206). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article.